vs
Generac（GNRC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Generac的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs 6.9%，领先5.8%），Generac同比增速更快（12.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $89.9M），过去两年Revvity的营收复合增速更高（9.0% vs 3.0%）
Generac Holdings Inc.（简称Generac）是美国财富1000强企业，主营面向住宅、小型商业及工业领域的备用发电产品，功率覆盖800瓦至9兆瓦，通过独立经销商、零售商及批发商渠道发售，总部位于威斯康星州沃基肖，在该州多地设有生产基地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GNRC vs RVTY — 直观对比
营收规模更大
GNRC
是对方的1.4倍
$772.1M
营收增速更快
GNRC
高出6.6%
5.9%
净利率更高
RVTY
高出5.8%
6.9%
自由现金流更多
RVTY
多$71.9M
$89.9M
两年增速更快
RVTY
近两年复合增速
3.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $73.1M | $98.4M |
| 毛利率 | 38.7% | — |
| 营业利润率 | 11.1% | 14.5% |
| 净利率 | 6.9% | 12.7% |
| 营收同比 | 12.4% | 5.9% |
| 净利润同比 | 65.1% | 3.9% |
| 每股收益（稀释后） | $1.24 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GNRCRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $942.1M | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $998.2M | $691.7M |
净利润GNRCRVTY
| Q1 26 | $73.1M | — | ||
| Q4 25 | $-24.5M | $98.4M | ||
| Q3 25 | $66.2M | $46.7M | ||
| Q2 25 | $74.0M | $53.9M | ||
| Q1 25 | $43.8M | $42.2M | ||
| Q4 24 | $117.2M | $94.6M | ||
| Q3 24 | $113.7M | $94.4M | ||
| Q2 24 | $59.1M | $55.4M |
毛利率GNRCRVTY
| Q1 26 | 38.7% | — | ||
| Q4 25 | 36.3% | — | ||
| Q3 25 | 38.3% | 53.6% | ||
| Q2 25 | 39.3% | 54.5% | ||
| Q1 25 | 39.5% | 56.5% | ||
| Q4 24 | 40.6% | — | ||
| Q3 24 | 40.2% | 56.3% | ||
| Q2 24 | 37.6% | 55.7% |
营业利润率GNRCRVTY
| Q1 26 | 11.1% | — | ||
| Q4 25 | -0.9% | 14.5% | ||
| Q3 25 | 9.3% | 11.7% | ||
| Q2 25 | 10.5% | 12.6% | ||
| Q1 25 | 8.9% | 10.9% | ||
| Q4 24 | 16.0% | 16.3% | ||
| Q3 24 | 14.4% | 14.3% | ||
| Q2 24 | 10.3% | 12.4% |
净利率GNRCRVTY
| Q1 26 | 6.9% | — | ||
| Q4 25 | -2.2% | 12.7% | ||
| Q3 25 | 5.9% | 6.7% | ||
| Q2 25 | 7.0% | 7.5% | ||
| Q1 25 | 4.7% | 6.4% | ||
| Q4 24 | 9.5% | 13.0% | ||
| Q3 24 | 9.7% | 13.8% | ||
| Q2 24 | 5.9% | 8.0% |
每股收益（稀释后）GNRCRVTY
| Q1 26 | $1.24 | — | ||
| Q4 25 | $-0.41 | $0.86 | ||
| Q3 25 | $1.12 | $0.40 | ||
| Q2 25 | $1.25 | $0.46 | ||
| Q1 25 | $0.73 | $0.35 | ||
| Q4 24 | $2.14 | $0.77 | ||
| Q3 24 | $1.89 | $0.77 | ||
| Q2 24 | $0.97 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $265.5M | $919.9M |
| 总债务越低越好 | $44.0M | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $5.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资GNRCRVTY
| Q1 26 | $265.5M | — | ||
| Q4 25 | $341.4M | $919.9M | ||
| Q3 25 | $300.0M | $931.4M | ||
| Q2 25 | $223.5M | $991.8M | ||
| Q1 25 | $187.5M | $1.1B | ||
| Q4 24 | $281.3M | $1.2B | ||
| Q3 24 | $214.2M | $1.2B | ||
| Q2 24 | $218.3M | $2.0B |
总债务GNRCRVTY
| Q1 26 | $44.0M | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — |
股东权益GNRCRVTY
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.6B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $2.5B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B |
总资产GNRCRVTY
| Q1 26 | $5.6B | — | ||
| Q4 25 | $5.6B | $12.2B | ||
| Q3 25 | $5.6B | $12.1B | ||
| Q2 25 | $5.4B | $12.4B | ||
| Q1 25 | $5.1B | $12.4B | ||
| Q4 24 | $5.1B | $12.4B | ||
| Q3 24 | $5.2B | $12.8B | ||
| Q2 24 | $5.1B | $13.4B |
负债/权益比GNRCRVTY
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $119.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $89.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.5% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.63× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $330.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GNRCRVTY
| Q1 26 | $119.3M | — | ||
| Q4 25 | $189.3M | $182.0M | ||
| Q3 25 | $118.4M | $138.5M | ||
| Q2 25 | $72.2M | $134.3M | ||
| Q1 25 | $58.2M | $128.2M | ||
| Q4 24 | $339.5M | $174.2M | ||
| Q3 24 | $212.3M | $147.9M | ||
| Q2 24 | $77.7M | $158.6M |
自由现金流GNRCRVTY
| Q1 26 | $89.9M | — | ||
| Q4 25 | $129.9M | $161.8M | ||
| Q3 25 | $96.5M | $120.0M | ||
| Q2 25 | $14.5M | $115.5M | ||
| Q1 25 | $27.2M | $112.2M | ||
| Q4 24 | $286.1M | $149.8M | ||
| Q3 24 | $183.7M | $125.6M | ||
| Q2 24 | $49.7M | $136.6M |
自由现金流率GNRCRVTY
| Q1 26 | 8.5% | — | ||
| Q4 25 | 11.9% | 21.0% | ||
| Q3 25 | 8.7% | 17.2% | ||
| Q2 25 | 1.4% | 16.0% | ||
| Q1 25 | 2.9% | 16.9% | ||
| Q4 24 | 23.2% | 20.5% | ||
| Q3 24 | 15.6% | 18.4% | ||
| Q2 24 | 5.0% | 19.7% |
资本支出强度GNRCRVTY
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 2.6% | ||
| Q3 25 | 2.0% | 2.6% | ||
| Q2 25 | 5.4% | 2.6% | ||
| Q1 25 | 3.3% | 2.4% | ||
| Q4 24 | 4.3% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 2.8% | 3.2% |
现金转化率GNRCRVTY
| Q1 26 | 1.63× | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 1.79× | 2.97× | ||
| Q2 25 | 0.98× | 2.49× | ||
| Q1 25 | 1.33× | 3.03× | ||
| Q4 24 | 2.90× | 1.84× | ||
| Q3 24 | 1.87× | 1.57× | ||
| Q2 24 | 1.31× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GNRC
| Residential | $549.3M | 52% |
| Commercial & Industrial | $510.0M | 48% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
